Mission statement

InterCure Announces Record Preliminary Third Quarter Revenue of CAD$24 million - 3 Times YOY and 36% QOQ Growth

Retrieved on: 
Monday, October 25, 2021

(NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the Company) today announced preliminary unaudited revenue of CAD$24 million (NIS 61 million) for the third quarter of 2021, representing another record quarter of high sequential and year-over-year revenue growth.

Key Points: 
  • (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the Company) today announced preliminary unaudited revenue of CAD$24 million (NIS 61 million) for the third quarter of 2021, representing another record quarter of high sequential and year-over-year revenue growth.
  • The Company plans to file its full financial results for the third quarter of 2021 on Monday, November 15, 2021.
  • Legislation of adult-use cannabis and CBD products in Israel is expected to drive further domestic demand for the Companys products.
  • InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America.

APi Group Announces Date for Third Quarter 2021 Earnings Release

Retrieved on: 
Friday, October 22, 2021

APi Group Corporation (NYSE: APG) (APG, APi or the Company), announced today that it intends to release its third quarter financial results for the three months ended September 30, 2021 before the market opens on Wednesday, November 10, 2021.

Key Points: 
  • APi Group Corporation (NYSE: APG) (APG, APi or the Company), announced today that it intends to release its third quarter financial results for the three months ended September 30, 2021 before the market opens on Wednesday, November 10, 2021.
  • APi expects net revenues for the three months ended September 30, 2021 to be at the higher end of analysts' expectations.
  • APi will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Wednesday, November 10, 2021.
  • The Companys independent registered public accounting firm has not completed its review of the Companys results for the quarter ended September 30, 2021.

Juniata Valley Financial Corp. Announces Third Quarter 2021 Results

Retrieved on: 
Friday, October 22, 2021

Juniata Valley Financial Corp. (OTC Pink: JUVF) (Juniata), announced net income for the quarter ended September 30, 2021 of $1.9 million, an increase of 18.1%, compared to net income of $1.6 million for the quarter ended September 30, 2020.

Key Points: 
  • Juniata Valley Financial Corp. (OTC Pink: JUVF) (Juniata), announced net income for the quarter ended September 30, 2021 of $1.9 million, an increase of 18.1%, compared to net income of $1.6 million for the quarter ended September 30, 2020.
  • Juniata funded an additional 362 PPP loans, totaling $18.9 million, through the second round of PPP funding in 2021.
  • The Juniata Valley Bank, the principal subsidiary of Juniata Valley Financial Corp., is headquartered in Mifflintown, Pennsylvania, with nineteen community offices located in Juniata, Mifflin, Perry, Huntingdon, McKean and Potter Counties.
  • More information regarding Juniata Valley Financial Corp. and The Juniata Valley Bank can be found online at www.JVBonline.com.

Theratechnologies Announces Publication in Frontiers in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry

Retrieved on: 
Friday, October 22, 2021

The formation of microvascular channels by deregulated cancer cells leads to aggressive, metastatic and resistant cancer cells and is known as vasculogenic mimicry.

Key Points: 
  • The formation of microvascular channels by deregulated cancer cells leads to aggressive, metastatic and resistant cancer cells and is known as vasculogenic mimicry.
  • VM is believed to be associated with tumor growth, resistance and poor prognosis in many types of aggressive cancers including ovarian and TNBC.
  • Theratechnologies is currently developing a platform of new proprietary peptides for cancer drug development targeting SORT1 receptors called SORT1+ TechnologyTM.
  • TH1902 is currently Theratechnologies lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology.

Rochon Genova LLP and KND Complex Litigation Announce Securities Class Action on Behalf of Investors of Akumin Inc.

Retrieved on: 
Friday, October 22, 2021

TORONTO, Oct. 22, 2021 /CNW/ -Rochon Genova LLP and KND Complex Litigation announce that a class action lawsuit has been commenced against Akumin Inc. (TSE: AKU) (NASDAQ: AKU) and certain of its directors and officers on behalf of investors.

Key Points: 
  • TORONTO, Oct. 22, 2021 /CNW/ -Rochon Genova LLP and KND Complex Litigation announce that a class action lawsuit has been commenced against Akumin Inc. (TSE: AKU) (NASDAQ: AKU) and certain of its directors and officers on behalf of investors.
  • The action seeks to recover damages on behalf of the investors.
  • According to the report, the additional information and analysis related to potential additional credit losses with respect to prior years.
  • On October 12, 2021, Akumin reported that it had identified accounting errors in its financial statements for current and past reporting periods affecting its accounts receivable.

Intercept Music, a Sanwire Corp Subsidiary, Appoints Tory "Flossy the Boss" Harrelson as Vice President of Business Development

Retrieved on: 
Friday, October 22, 2021

Flossy The Boss will be charged with enrolling independent music labels for Intercept Music services.

Key Points: 
  • Flossy The Boss will be charged with enrolling independent music labels for Intercept Music services.
  • In the last year alone, Intercept Music has added a roster of 40 independent labels, representing hundreds of artists.
  • Combined with global distribution through Ingrooves/UMG, independent labels using Intercept Music have an unmatched array of tools to make their artists successful.
  • Flossy The Boss comes to Intercept Music as a respected leader with decades of success generating revenue for labels and artists.

Tencent Music Entertainment Group to Hold Annual General Meeting on December 17, 2021

Retrieved on: 
Friday, October 22, 2021

Shareholders and ADS holders may access the Company's 2020 annual report on the Company's investor relations website at https://ir.tencentmusic.com as well as the SEC's website at http://www.sec.gov .

Key Points: 
  • Shareholders and ADS holders may access the Company's 2020 annual report on the Company's investor relations website at https://ir.tencentmusic.com as well as the SEC's website at http://www.sec.gov .
  • Tencent Music Entertainment Group (NYSE: TME) is the leading online music and audio entertainment platform in China, operating the country's highly popular and innovative music apps: QQ Music, Kugou Music, Kuwo Music and WeSing.
  • Tencent Music's mission is to use technology to elevate the role of music in people's lives by enabling them to create, enjoy, share and interact with music.
  • Tencent Music's platform comprises online music, online audio, online karaoke, music-centric live streaming and online concert services, enabling music fans to discover, listen, sing, watch, perform and socialize around music.

Medigus: Polyrizon to Initiate Processes Towards FDA Submission

Retrieved on: 
Friday, October 22, 2021

Tel Aviv, Israel, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that Polyrizon Ltd., (37.01%), that it has engaged with a full-service Contract Research Organisation (CRO), to advise the Company in its pursuit of Food and Drug Administration (FDA) submission for its products.

Key Points: 
  • Polyrizon and the CRO will start working on a readiness plan for Polyrizons preventative products for SARS-CoV-2, coronavirus, influenza and allergens, in order to prepare for U.S FDA submission.
  • Polyrizon recently submitted a patent application for its products preventing of pathogens such as coronavirus and allergens from affecting nasal tissue.
  • For example, Medigus uses forward looking statements when describing the potential of Polyrizons product candidates and plans for FDA submissions.
  • Other risk factors affecting Medigus and Polyrizon are discussed in detail in the Medigus filings with the Securities and Exchange Commission.

Audit Sight Raises $2.5 Million from Hyde Park Venture Partners to Simplify and Strengthen the Painful Auditing Process

Retrieved on: 
Friday, October 22, 2021

Ira Weiss, partner at Hyde Park Venture Partners, has joined the Audit Sight board as part of the financing.

Key Points: 
  • Ira Weiss, partner at Hyde Park Venture Partners, has joined the Audit Sight board as part of the financing.
  • At the heart of the audit process is detailed testing of the underlying accounting transactions against source documentation.
  • Once the client connects their accounts, Audit Sight digitally gathers the data needed for the audit tests.
  • Whittaker and Womack previously worked at PwC, where they became intimately familiar with the auditing process and its pain points.

FTS International Announces Preliminary Third Quarter 2021 Financial and Operational Results

Retrieved on: 
Friday, October 22, 2021

The Companys actual results may differ from these preliminary financial and operational results due to the completion of the Companys financial closing procedures, final adjustments and other developments that may arise between the date of this announcement and when results for the third quarter 2021 are finalized.

Key Points: 
  • The Companys actual results may differ from these preliminary financial and operational results due to the completion of the Companys financial closing procedures, final adjustments and other developments that may arise between the date of this announcement and when results for the third quarter 2021 are finalized.
  • The preliminary financial and operational results included in this announcement are not a comprehensive statement of the Companys financial results and are subject to risks and uncertainties and should not be viewed as a substitute for full financial statements prepared in accordance with GAAP.
  • Because of these limitations, you should consider adjusted EBITDA alongside other financial performance measures, including net loss and our other GAAP results.
  • The table included under Reconciliation of Preliminary Net Loss to Adjusted EBITDA provides a reconciliation of preliminary net loss to adjusted EBITDA for the third quarter 2021.